Veronica Bernabucci

TL;DR: In this article, a randomized controlled trial was performed to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis.

TL;DR: In a small randomized controlled trial, a 12-month course of enoxaparin was safe and effective in preventing PVT in patients with cirrhosis and a Child-Pugh score of 7-10 and to improve survival.

TL;DR: A 10-day sequential regimen (40 mg of pantoprazole, 1 g of amoxicillin, and placebo, each administered twice daily for the first 5 days, followed by 40 mg of Pantoprazle, 500 mg of clarithromycin, and 500 mg tinidazole, each averaged twice daily, for the remaining 5 days) or standard 10 days therapy was shown to be significantly more effective in patients with H. pylori-resistant strains.

TL;DR: The eradication rate of H. pylori infection was greater with the sequential regimen than with the standard treatment and the effect of clarithromycin and metronidazole resistance on the outcome of sequential therapy has not been studied prospectively.

TL;DR: A standard third‐line treatment is lacking, and European guidelines recommend performing culture in patients, but the use of this procedure as ‘routine practice’ is definitively not feasible.